Probiotics for chronic low back pain with type 1 Modic changes: a randomized double-blind, placebo-controlled trial with 1-year follow-up using Lactobacillus Rhamnosis GG
To investigate whether treatment by lactic acid bacteria for 100 days is associated with change of disability and pain in chronic low back pain (CLBP) patients with type 1 or mixed Modic changes (MC) during 1-year follow-up.
Eighty-nine patients with CLBP and type 1 MC or mixed MC were randomized to receive either one capsule Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily or placebo capsules for 100 days.
Missing values at 1 year were 4% and 3% in the disability and pain variables, respectively. The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups. At 1 year, back pain had on average decreased by 1.1 more on a 0–10 scale (95% confidence interval 0.20–1.97) in the group treated by lactic acid bacteria than in the control group. There were no differences regarding other predefined outcomes, i.e. global effect or percentage with minimal disability at 1 year. Nine per cent of the patients reported gastrointestinal side effects without difference between groups.
No differences were found regarding the predefined outcomes. Overall, there was little improvement during the 1-year observation period. A small, though hardly clinically relevant, effect on back pain was seen after treatment by Lactobacillus Rhamnosis GG, and the treatment was without side effects in comparison with the control group.
KeywordsModic changes Chronic low back pain Probiotics Lactic acid bacteria Inflammation Vertebral end-plate oedema
We would like to thank associated professor, Ph.D., Christian Lodberg Hvas, specialist of Gastroenterology, for fruitful discussions in regard to design of this study, although his recommendations of faecal sampling could not be followed. Furthermore, we would like to thank physiotherapist Anders Boes (†) and Secretary Maiken Madsen for their enthusiastic and thorough work ensuring relevant guidance and advice for the patients participating in this study.
The study has been supported by The Danish Rheumatism Association and Peter and Helga Korningsfond. This study was funded by Gigtforeningen (Grant No. R139-A3924)
Compliance with ethical standards
Conflict of interest
Ole Kudsk Jensen, Morten Hovgaard Andersen, René Drage Østgård, Niels Trolle Andersen and Nanna Rolving declare that they have no conflict of interest.
Ethics approval was obtained from the institutional review board before commencement of this study. No benefits in any form have been or will be received from any commercial party related directly or indirectly to the subject of this manuscript.
- 2.Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S, Brodt ED (2017) Nonpharmacologic therapies for low back pain: a systematic review for an American college of physicians clinical practice guideline. Ann Intern Med 166(7):493–505CrossRefGoogle Scholar
- 4.Waddell G (2004) The back pain revolution. Churchill Livingstone, EdinburghGoogle Scholar
- 10.Ohtori S, Inoue G, Ito T, Koshi T, Ozawa T, Doya H, Saito T, Moriya H, Takahashi K (2006) Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI. Spine (Phila Pa 1976) 31(9):1026–1031CrossRefGoogle Scholar
- 13.Al-Falahi Mohanned A, Salal Mohammed H, Abdul-Wahab Dhiaa M (2014) Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (modic type i changes): a randomized clinical controlled trial of efficacy. Iraqui Postgrad Med J 13(3):390–397Google Scholar
- 16.Albert HB, Jensen AM, Dahl D, Rasmussen MN (2003) [Criteria validation of the Roland Morris questionnaire. A Danish translation of the international scale for the assessment of functional level in patients with low back pain and sciatica]. Ugeskr Laeger 165(18):1875–1880Google Scholar
- 19.Stata Statistical Software (2005) Release 9. StataCorp LP, College StationGoogle Scholar
- 23.Jethwa H, Abraham S (2017) The evidence for microbiome manipulation in inflammatory arthritis. Rheumatology (Oxford) 56(9):1452–1460Google Scholar